Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study

Alkermes plc (ALKS) announced positive top-line data from a phase Ib study evaluating its novel, investigational, oral orexin 2 receptor (OX2R) agonist, ALKS 2680, as a once-daily treatment for narcolepsy.The above data was from the narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) cohorts of the early-stage proof-of-concept study, which evaluated ALKS 2680 for the given indication.The phase Ib NT2 and IH study cohorts investigated the safety, tolerability, pharmacokinetics and pharmacodynamics of var ...